神经损伤与功能重建Issue(4)：295-297,3.DOI:10.3870/sjsscj.2015.04.005
癫痫患者 CYP2C19基因多态性对丙戊酸钠血药浓度的影响
Effects of CYP2C19 Genetic Polymorphism on Plasma Concentration of Sodium Valproate in ;Epileptic Patients
摘要
Abstract
Objective:To screen the influence of the functional polymorphisms of cytochrome P450 2C19 (CYP2C19) on plasma concentration of sodium valproate (VPA) in epileptic patients. Methods: One hundred and seventy-seven epileptic patients who were treated with VPA, hospitalized in neurology and neurosurgery of Renmin Hospital of Wuhan University were selected. Enzyme-multiplied immunoassay technique was used to measure the plasma concentration of VPA. Gene chips were used to detect VPA metabolism related CYP2C19 genotypes (*l, *2,*3). According to the genotypes, all patients were divided into 3 groups: strong metabolism type (*1/*1) group, in-termediate metabolism type (*1/*2, *1/*3) group, poor metabolism type (*2/*2, *3/*3, *2/*3) group. The plasma concentrations of VPA of the three groups were compared. Results: According to the function of CYP2C19 gene polymorphisms of metabolic type, strong metabolic type carrying CYP2C19*1 (*1/*1) accounted for 40.7%, inter-mediate metabolizers carrying CYP2C19*2 or *3 (*1/*2 and *1/*3) and poor metabolizers (*2/*2, *2/*3 and *3/*3) accounted for 43.5% and 15.8%, respectively. Gender had no effect on CYP2C19 genotype differences. Standard-ization of plasma VPA concentration in poor metabolizers was (3.78±1.08) μg/mL, which was statistically higher than those in the other two metabolic types [(2.69±0.48) μg/mL and (2.71±0.33) μg/mL] (P<0.05). Conclusion:CYP2C19 gene with functional deletion was observed in epileptic patients in Wuhan area, while doctors can refer to relevant gene detection results to reduce the VPA dose in poor metabolic patients.关键词
癫痫/丙戊酸钠/CYP2C19 基因/基因多态性/血药浓度Key words
epilepsy/sodium valproate/CYP2C19 gene/genetic polymorphism/serum concentration分类
医药卫生引用本文复制引用
韩瑞玲,李艳,吴薇..癫痫患者 CYP2C19基因多态性对丙戊酸钠血药浓度的影响[J].神经损伤与功能重建,2015,(4):295-297,3.基金项目
国家自然科学基金 （）
